REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
02/15/2026
Back to search
Official data from USPTO
ADLIB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
58
Latest update
02/16/2026
Trademark type
Word
Nice classes
5, 42
Filing date
04/28/2015
Registration date
02/14/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/10/2023
Last transaction
02/16/2026
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Tokyo, JP
Examiner
MAHONEY, PAULA M
Law office
N10
Holders and representatives
Holders
Chiome Bioscience Inc.
Representatives
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Monoclonal antibodies for medical or veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; peptides and proteins for medical or veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; medicines for human purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; medicines for dental purposesfor infectious diseasesneurological diseases or inflammatory diseases; medicines for veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; medicinal preparationsfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposesfor cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implantsa vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin
Class 42
Researchproduct development and quality control services in the field of proteinsantibodiesmicroorganisms and cellsconsultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products * Researchproduct development and quality control services in the field of proteinsantibodiesmicroorganisms and cellsconsultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals *
Publications
History of USPTO decisions and trademark events.
58 publications found
RNWL
INTERNATIONAL REGISTRATION RENEWED
04/24/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/18/2025
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
04/01/2024
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
02/26/2024
INPC
INVALIDATION PROCESSED
02/26/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
02/10/2024
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
06/10/2023
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
06/10/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/29/2023
ES71
TEAS SECTION 71 RECEIVED
11/15/2022
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/14/2022
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
03/07/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
02/23/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/28/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/15/2017
FIMP
FINAL DISPOSITION PROCESSED
09/15/2017
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/04/2017
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
06/23/2017
PLGL
ASSIGNED TO PARALEGAL
06/06/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/14/2017
ES7R
TEAS SECTION 7 REQUEST RECEIVED
03/09/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
02/14/2017
CHPN
POST PUBLICATION AMENDMENT – NOT ENTERED
02/01/2017
APET
ASSIGNED TO PETITION STAFF
01/31/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/28/2016
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/28/2016
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/16/2016
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
12/16/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/29/2016
PUBO
PUBLISHED FOR OPPOSITION
11/29/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/09/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/09/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/09/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/27/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/13/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/24/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/23/2016
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
09/23/2016
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
09/19/2016
ALIE
ASSIGNED TO LIE
09/15/2016
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/10/2016
GNSL
LETTER OF SUSPENSION E-MAILED
03/10/2016
CNSL
SUSPENSION LETTER WRITTEN
03/10/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/16/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/15/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/15/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/15/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/15/2016
RFNT
REFUSAL PROCESSED BY IB
09/04/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/14/2015
RFRR
REFUSAL PROCESSED BY MPU
08/14/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/14/2015
CNRT
NON-FINAL ACTION WRITTEN
08/13/2015
DOCK
ASSIGNED TO EXAMINER
08/08/2015
MAFR
APPLICATION FILING RECEIPT MAILED
07/29/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/25/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/23/2015
Continuous trademark protection
Get notified about every new filing that threatens ADLIB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.